Almost 200,000 people have fatally overdosed on opioids in the past 15 years, with more than 30,000 people dying in 2015 alone. » Read More
By: Rebecca Robbins
A billionaire doctor who's been spotted with Trump promoted a questionable therapy on his Twitter, STAT News reports. » Read More
Europe's medicines regulator has recommended the suspension of generic drug approvals due to "unreliable" tests conducted by an Indian firm. » Read More
By: Harriet Lefton of TipRanks
TipRanks identified the corporate insiders with the best-performing track records and the stocks they are buying. » Read More
The lack of clarity over Trump’s policies was so great that fund manager Invesco is reducing risk exposure, a senior portfolio manager said.
The new CMS classification means the device is eligible for Medicaid and Medicare coverage.
It's becoming obvious Big Pharma's iron wall of protection in Washington is starting to crumble, says Jake Novak.
Price and Rep. Chris Collins, R-N.Y., got a 12 percent discount in their private placement purchase of stock in an Australian drug company.
"Sugar Goggles," a virtual reality game, is hoping to encourage children to make healthier eating choices and adjust eating habits.
When someone goes into opioid overdose, their body begins shutting down. But there’s a drug that can stop the process. Naloxone has saved the thousands of people after they overdosed. Here’s how it works.
Investor optimism regarding the outlook for European healthcare stocks continued to decline dramatically on Thursday.
Morgan Stanley's 2020 earnings-per-share estimate for Merck is $5.82 versus the Wall Street consensus of $4.97.
Andrew Keene at KeeneOnTheMarket.com says that Trump is still better for pharmaceutical stocks than Clinton would have been.
Shkreli, who is accused of securities fraud, is free on $5 million bail, and normally must stay in New York.
Chris Meekins, FBR Capital Markets research analyst, and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss President-elect Trump's comments on drug pricing and their effect on biotech and pharma stocks.
CNBC's Bob Pisani and Art Cashin, of UBS, discuss the market’s reaction to President-elect Donald Trump’s first news conference since Election Day.
Trump's Obamacare remarks came at a news conference that was his first since being elected president of the United States.
On Wednesday, President-elect Donald Trump held his first news conference since his election in November.
The "Squawk on the Street" crew discuss the new leadership group in the markets: biotech stocks.
Gilead CEO John Milligan made his comments on CNBC's "Fast Money" on Tuesday.
"I truly understand the outrage when you have no idea what something's going to cost," said Heather Bresch.
Mylan CEO Heather Bresch speaks to CNBC's Meg Tirrell about the future of EpiPen pricing under President-elect Donald Trump as he pushes to bring drug prices down.
Mylan CEO Heather Bresch speaks to CNBC's Meg Tirrell about the future of EpiPen pricing.
Dr. Ed Kaye gives an update on Sarepta Therapeutics in an exclusive interview with CNBC's Meg Tirrell.
Get the best of CNBC in your inbox